The aim of the study is to evaluate the influence of sarcosine therapy on the concentrations of NAA, Glx (complex of glutamate, glutamine and γ-aminobutyric acid GABA), mI (myo-inositol), Cho (choline-containing compounds) and Cr (creatine plus phosphocreatine) in the DLPFC of the left frontal lobe in patients with schizophrenia. Our experiment can support new data on the pharmacokinetics, pharmacodynamics and psychopharmacological value of sarcosine, as well as glutamatergic agents in general. It can also reveal new aspects of the role played by the glutamatergic system in the pathogenesis of schizophrenia.
